Upstream Bio, Inc. (UPB)
UPB moved a median of +0.58% 30 minutes after news, and +1.16% by the close. How UPB actually reacts to news — the realized, point-in-time move the market made, measured across 161 labeled events over the last three years with zero look-ahead.
UPB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.32% | 55% | 157 |
| 30-min | +0.58% | 58% | 158 |
| 60-min | +0.15% | 58% | 158 |
| to close | +1.16% | 62% | 158 |
| Middle 50% of UPB reactions | -0.75% to +1.89% |
|---|---|
| Median reaction (30-min) | +0.58% |
| Measured reactions | 161 |
Half of all Upstream Bio, Inc. news events land between -0.75% and +1.89% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when UPB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to UPB's baseline. Nothing else.
Recent UPB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 | Press release | GlobeNewswire | -3.66% | +3.00% | |
| Form 8-K Upstream Bio, Inc. For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | -0.61% | -0.46% | |
| Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP | Press release | GlobeNewswire | -0.61% | -0.46% | |
| Form 10-Q Upstream Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.94% | -5.21% | |
| Form 8-K Upstream Bio, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.94% | -5.21% | |
| Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress | Press release | GlobeNewswire | -0.94% | -5.21% | |
| Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 | Press release | GlobeNewswire | -0.48% | -1.45% | |
| Form 8-K Upstream Bio, Inc. For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | -1.83% | +1.59% | |
| Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 | Press release | GlobeNewswire | -1.82% | -9.92% | |
| Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | Press release | GlobeNewswire | -1.33% | +1.46% | |
| Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference | Press release | GlobeNewswire | -0.47% | -0.35% | |
| Form 10-Q Upstream Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +4.46% | |
| Form 8-K Upstream Bio, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.46% | |
| Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +0.00% | +4.46% | |
| Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference | Press release | GlobeNewswire | +0.96% | -4.40% | |
| Form ARS Upstream Bio, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.96% | -4.40% | |
| Form DEF 14A Upstream Bio, Inc. For: Jun 09 | SEC filing · Form DEF | SEC EDGAR | +0.96% | -4.40% | |
| Form DEFA14A Upstream Bio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.96% | -4.40% | |
| Form 10-K Upstream Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.86% | -0.57% | |
| Form 8-K Upstream Bio, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +3.27% | |
| Form S-8 Upstream Bio, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.86% | -0.57% | |
| Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.32% | +3.27% | |
| Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting | Press release | GlobeNewswire | +3.73% | +2.53% | |
| Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 | Press release | GlobeNewswire | +2.39% | +2.07% | |
| Upstream Bio to Participate in Upcoming March Investor Conferences | Press release | GlobeNewswire | +1.77% | -2.02% | |
| Form 8-K Upstream Bio, Inc. For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -7.63% | -22.68% | |
| Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | Press release | GlobeNewswire | -7.63% | -22.68% | |
| Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma | Press release | GlobeNewswire | -7.63% | -22.68% | |
| Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.83% | -3.47% | |
| Upstream Bio to Participate in Upcoming December Investor Conferences | Press release | GlobeNewswire | +0.29% | +9.95% | |
| Form 10-Q Upstream Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.15% | -5.78% | |
| Form 8-K Upstream Bio, Inc. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -4.15% | -5.78% | |
| Form S-3ASR Upstream Bio, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -4.15% | -5.78% | |
| Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress | Press release | GlobeNewswire | -4.15% | -5.78% | |
| Upstream Bio to Participate in Upcoming November Investor Conferences | Press release | GlobeNewswire | -0.78% | +0.58% | |
| Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress | Press release | GlobeNewswire | -1.15% | +8.48% | |
| Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum | Press release | GlobeNewswire | +0.16% | -2.56% | |
| Form 8-K Upstream Bio, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +3.33% | +21.61% | |
| Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Press release | GlobeNewswire | +3.33% | +21.61% | |
| Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | Press release | GlobeNewswire | +3.33% | +21.61% | |
| Form 10-Q Upstream Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.26% | +10.07% | |
| Form 8-K Upstream Bio, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.26% | +10.07% | |
| Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress | Press release | GlobeNewswire | +0.26% | +10.07% | |
| Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | Press release | GlobeNewswire | +0.05% | -0.73% | |
| Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor | Press release | GlobeNewswire | +0.00% | -2.53% | |
| Form 8-K Upstream Bio, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | +1.43% | |
| Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 | Press release | GlobeNewswire | -1.38% | -0.18% | |
| Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference | Press release | GlobeNewswire | +2.54% | +0.18% | |
| Upstream Bio Appoints Stacy Price as Chief Technology Officer | Press release | GlobeNewswire | -0.66% | +1.11% | |
| Form 10-Q Upstream Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -4.20% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the UPB section they belong to.
Where else UPB is measured.
UPB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Upstream Bio, Inc.'s median reaction calculated?
Every labeled UPB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 161 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 58% of UPB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does UPB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.